NASDAQ:MXCT

MaxCyte (MXCT) Stock Price, News & Analysis

$3.80
-0.16 (-4.04%)
(As of 04/23/2024 ET)
Today's Range
$3.78
$4.12
50-Day Range
$3.80
$4.79
52-Week Range
$2.45
$5.55
Volume
569,042 shs
Average Volume
636,658 shs
Market Capitalization
$396.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.67

MaxCyte MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
128.1% Upside
$8.67 Price Target
Short Interest
Bearish
3.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of MaxCyte in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$47,650 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.53) to ($0.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.42 out of 5 stars

Medical Sector

689th out of 909 stocks

Commercial Physical Research Industry

10th out of 12 stocks

MXCT stock logo

About MaxCyte Stock (NASDAQ:MXCT)

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

MXCT Stock Price History

MXCT Stock News Headlines

The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
MaxCyte Signs SPL Agreement With Imugene
COMM, NKTX and AVIR are among after hour movers
MaxCyte gets new CEO and President
MaxCyte Names Maher Masoud CEO
See More Headlines
Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/12/2024
Today
4/23/2024
Next Earnings (Confirmed)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:MXCT
Employees
143
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.67
High Stock Price Target
$11.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+125.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-37,920,000.00
Pretax Margin
-91.85%

Debt

Sales & Book Value

Annual Sales
$41.29 million
Book Value
$2.23 per share

Miscellaneous

Free Float
98,132,000
Market Cap
$400.88 million
Optionable
Optionable
Beta
1.34
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Maher Masoud (Age 48)
    President, CEO, Secretary & Director
    Comp: $612.07k
  • Mr. Douglas Arthur Doerfler (Age 68)
    Founder
    Comp: $1.2M
  • Mr. Douglas J. Swirsky CFA (Age 55)
    CPA, Chief Financial Officer
  • Mr. Jay Gelfman
    Senior Vice President of Operations
  • Mr. Ronald Evan Holtz CPA (Age 66)
    Ph.D., Executive Vice President of Administration
    Comp: $649.38k
  • Mr. Sean Menarguez
    Director of Investor Relations
  • Mr. David Sandoval
    Senior Vice President & General Counsel
  • Mr. Thomas Michael Ross (Age 63)
    Executive Vice President of Global Sales
  • Mr. Jack Horgan
    Vice President of Corporate Development
  • Ms. Jill Mayer
    Senior Vice President of Human Resources

MXCT Stock Analysis - Frequently Asked Questions

Should I buy or sell MaxCyte stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MXCT shares.
View MXCT analyst ratings
or view top-rated stocks.

What is MaxCyte's stock price target for 2024?

4 Wall Street analysts have issued 1-year target prices for MaxCyte's shares. Their MXCT share price targets range from $7.00 to $11.00. On average, they anticipate the company's share price to reach $8.67 in the next year. This suggests a possible upside of 128.1% from the stock's current price.
View analysts price targets for MXCT
or view top-rated stocks among Wall Street analysts.

How have MXCT shares performed in 2024?

MaxCyte's stock was trading at $4.70 at the beginning of 2024. Since then, MXCT stock has decreased by 19.1% and is now trading at $3.80.
View the best growth stocks for 2024 here
.

When is MaxCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our MXCT earnings forecast
.

How can I listen to MaxCyte's earnings call?

MaxCyte will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were MaxCyte's earnings last quarter?

MaxCyte, Inc. (NASDAQ:MXCT) issued its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05. The business had revenue of $15.67 million for the quarter, compared to analysts' expectations of $15.60 million. MaxCyte had a negative net margin of 91.85% and a negative trailing twelve-month return on equity of 15.90%.

What guidance has MaxCyte issued on next quarter's earnings?

MaxCyte issued an update on its FY 2024 earnings guidance on Monday, March, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $29.6 million-$31.3 million, compared to the consensus revenue estimate of $42.1 million.

When did MaxCyte IPO?

MaxCyte (MXCT) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share.

Who are MaxCyte's major shareholders?

MaxCyte's stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.27%) and Salem Investment Counselors Inc. (0.05%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, John Joseph Johnston, Richard Douglas and Thomas M Ross.
View institutional ownership trends
.

How do I buy shares of MaxCyte?

Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MXCT) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners